Nitric oxide metabolism in erythropoietin-induced hypertension: Effect of calcium channel blockade

Hypertension

Volumn 32, Issue 4, 1998, Pages 724-729

  Ni, Zhenmin ^a   Wang, Xiu Q ^a   Vaziri, Nosratola D ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Calcium; Calcium channel blockers; Erythropoietin; Hypertension; Nitric oxide synthase; Renal disease

Indexed keywords

CALCIUM CHANNEL BLOCKING AGENT; ERYTHROPOIETIN; FELODIPINE; NITRIC OXIDE; NITRIC OXIDE SYNTHASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CALCIUM CELL LEVEL; CONTROLLED STUDY; DRUG EFFECT; DRUG SCREENING; HYPERTENSION; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT;

EID: 0031724865     PISSN: 0194911X     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.HYP.32.4.724     Document Type: Article

References (28)

1. Abraham PA, Macres MG. Blood pressure in hemodialysis patients during amelioration of anemia with erythropoietin. J Am Soc Nephrol. 1991;2:927-936.
2. Buckner FS, Eschbach JW, Haley NR, Davidson RC, Adamson JW. Hypertension following erythropoietin therapy in anemic hemodialysis patients. Am J Hypertens. 1990;3:947-955.
3. Raine AEG, Roger SD. Effects of erythropoietin on BP. Am J Kidney Dis. 1991;18:76-83.
4. Raine AEG. Hypertension, blood viscosity and cardiovascular morbidity in renal failure: implications of erythropoietin therapy. Lancet. 1988;1:97-99.
5. Steffen HM, Brunner R, Muller R, Dengenhardt S, Pollok M, Lang R, Baldamus CA. Peripheral hemodynamics, blood viscosity, and the reninangiotensin system in hemodialysis patients under therapy with recombinant human erythropoietin. Contrib Nephrol. 1989;76:292-298.
6. Neff MS, Kim KE, Persoff M, Onesti G, Swartz C. Hemodynamics of uremic anemia. Circulation. 1971;43:876-883.
7. Martin J, Moncada S. Blood pressure, erythropoietin and nitric oxide. Lancet. 1988;1:644. Letter.
8. Carlini R, Obialo CI, Rothstein M. Intravenous erythropoietin (rHuEPO) administration increases plasma endothelin and blood pressure in hemodialysis patients. Am J Hypertens. 1993;6:103-107.
9. Eggena P, Willsey P, Jamgotchian N, Truckenbrod L, Hu MS, Barrett JD, Eggena MP, Clegg K, Nakhoul F, Lee DBN. Influence of recombinant human erythropoietin on blood pressure and renin-angiotensin systems. Am J Physiol. 1991;261:E642-E646.
10. Heidenreich S, Rahn KH, Zidek W. Direct vasopressor effect of recombinant human erythropoietin on renal resistance vessels. Kidney Int. 1991;39:259-265.
11. Vazin ND, Zhou XJ, Naqvi F, Smith J, Oveisi F, Wang ZQ, Purdy RE. Role of nitric oxide resistance in erythrocyte-induced hypertension in rats with chronic renal failure. Am J Physiol. 1996:271 (Endocrinol Metab.):E113-E122.
12. Vazin ND, Ding Y, Ni Z, Gonick HC. Altered nitric oxide metabolism and increased oxygen free radical activity in lead-induced hypertension: effect of lazaroid therapy. Kidney Int. 1997;52:1042-1046.
13. Comini L, Bachetti T, Gaia G, Pasini E, Agnoletti L, Pepi P, Ceconi C, Curello S, Ferrari R. Aorta and skeletal muscle NO synthase expression in experimental heart failure. Mol Cell Cardiol. 1996;28:2241-2248.
14. Martin PY, Xu DL, Niederberger M, Weigert A, Tsai P, St. John J, Gines P, Schrier RW. Upregulation of endothelial constitutive NOS: a major role in the increased NO production in cirrhotic rats. Am J Physiol. 1996;270(Renal Fluid Electrolyte Physiol.):F494-F499.
15. Vaziri ND, Zhou XJ, Smith J, Oveisi F, Baldwin K, Purdy RE. In vivo and in vitro pressor effects of erythropoietin in rats. Am J Physiol. 1995;269(Renal Fluid Electrolyte Physiol.):F838-F845.
16. Vaziri ND, Ni Z, Wang XQ, Oveisi F, Zhou XJ. Down-regulation of nitric oxide synthase in chronic renal insufficiency: role of excess PTH. Am J Physiol. 1998;274(Renal Physiol.):642-649.
17. Lopes Ongil SL, Saura M, Rodrigues PM, Rodrigues PD. Recombinant human erythropoietin does not regulate the expression of endothelin-1 and constitutive nitric oxide synthase in vascular endothelial cell. Exp Nephrol. 1996;4:37-42.
18. Wilcox CS, Deng X, Doll AH, Snellen H, Welch WJ. Nitric oxide mediates renal vasodilation during erythropoietin-induced polycythemia. Kidney Int. 1993;44:430-435.
19. del Castillo D, Raij L, Shultz PJ, Tolins JP. The pressor effect of recombinant human erythropoietin is not due to decreased activity of the endogenous nitric oxide system. Nephrol Dial Transplant. 1995;10:505-508.
20. Tsukahara H, Hiraoka M, Hori C, Hata I, Okada T, Gejyo F, Sudo M. Chronic erythropoietin treatment enhances endogenous nitric oxide production in rat. Scand J Lab. Invest. 1997;57:487-494.
21. Awolesi MA, Sessa WC. Sumpio BE. Cyclic strain upregulates nitric oxide synthase in cultured bovine aortic endothelial cells. J Clin Invest. 1995;96:1445-1449.
22. Nava E, Luscher TF. Evidence for an increased production of nitric oxide in spontaneously hypertensive rats. Eur J Clin Invest. 1994;24(suppl 2):A264. Abstract.
23. Noris M, Morigi M, Donadelli R, Aiello S, Foppolo M, Todeschini M, Orisio S, Remuzzi G, Remuzzi A. Nitric oxide synthesis by cultured endothelial cells is modulated by flow conditions. Circ Res. 1995;76:536-543.
24. Pohl U, Holtz J, Busse R, Bassenge E. Crucial role of endothelium in the vasodilator response to increased flow in vivo. Hypertension. 1986;8:37-44.
25. Miller BA, Cheung JY. Mechanisms of erythropoietin signal transduction: involvement of calcium channels. Proc Soc Exp Biol Med. 1994;206:263-267.
26. 2+ channels: activation by phospholipase C-γ1. Kidney Int. 1998;53:1259-1268.
27. Paxton WG, Marrero MB, Klein JD, Delafontaine P, Berk BC, Bernstein KE. The angiotensin II AT1 receptor is tyrosine and serine phosphorylated and can serve as a substrate for the src family of tyrosine kinases. Biochem Biophys Res Commun. 1994;200:260-267.
28. - channels in mesangial cells. Am J Physiol. 1996;270:C1834-C1842.